Lung cancer is one of the most diagnosed diseases in men and women and is the leading cause of cancer-related mortality worldwide. The purpose of this study is to examine the impact of lung cancer on the role of iron status markers in patient serum. The present study included fifty (50) lung cancer patients (males and females) and forty (40) healthy subjects. The levels of iron status markers that include iron, ferritin, transferrin, transferrin saturation (TS%), total iron binding capacity (TIBC), and unsaturated iron binding capacity (UIBC) were estimated in the serum of lung cancer patients, as well as the value of interleukin 6 (IL-6) were recorded. Generally, the results of the present study revealed significant differences (p<0.05) in the levels of iron status markers and IL-6 in the serum of lung cancer patients in comparison with the control groups. The findings of this study suggest that these indicators play an important role in lung cancer at multiple levels and that the specific activity of these biomarkers may be relevant as an independent predictor of lung cancer disease progression.